CAPTRUST Financial Advisors
ELTX icon

CAPTRUST Financial Advisors’s Elicio Therapeutics ELTX Stock Holding History

CAPTRUST Financial Advisors’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-30
Closed – – 2634
2022
Q2 		$0 Buy
+30
New +$479 ﹤0.01% 4977

Other funds holding ELTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return

CAPTRUST Financial Advisors's ELTX Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Elicio Therapeutics (ELTX) in Q3 2022, closing a stake of 30 shares.

CAPTRUST Financial Advisors first reported a position in ELTX in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 38 funds tracked by Wall St. Rank hold ELTX as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Elicio Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 30 Elicio Therapeutics shares in Q3 2022.
  • CAPTRUST Financial Advisors first reported a position in Elicio Therapeutics in Q2 2022 and held it in 1 quarter.
  • CAPTRUST Financial Advisors's Elicio Therapeutics position peaked at $0 in Q2 2022.
  • 38 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.